Biomatters takes advantage of biological drug market
Local software developer says it can help pharmaceutical companies make drugs to target cancer.
Auckland-based software developer Biomatters has designed an antibody analysis platform, which it says could help pharmaceutical companies make drugs to target diseases such as cancer.
The 13-year-old company, which already has a genetic code data analysis tool called Geneious used by about 3000
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Calida Smylie
Mon, 30 Jan 2017
Mon, 30 Jan 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Biomatters takes advantage of biological drug market
64461